Add-on adefovir is superior to a switch to entecavir as rescue therapy for Lamivudine-resistant chronic hepatitis B.

Journal Article (Journal Article)

BACKGROUND/AIMS: Lamivudine (LAM) has been extensively used to treat hepatitis B, but high incidence of drug resistance has required rescue studies. We validated the optimum treatment strategy for LAM-resistant patients by means of a comparative study of add-on adefovir (ADV) and a switch to entecavir (ETV). METHODS: We assessed the virologic response in consecutive LAM-resistant patients who received add-on ADV or a switch to ETV. RESULTS: The mean reduction of serum hepatitis B virus (HBV) DNA levels was significantly less in the ETV group than in the add-on ADV group (-3.45 vs. -4.17; P = 0.047 at week 24 and -3.81 vs. -4.68 log(10) IU/mL; P = 0.044 at week 48). Achievement of undetectable HBV DNA was significantly lower in the ETV group than in the add-on ADV group (P = 0.043). Multivariate analysis showed that add-on ADV, baseline HBV DNA levels, and initial virologic response were significant predictors of HBV DNA negativity (adjusted OR, 2.582; P = 0.008, 0.304; P = 0.001, and 5.928; P = 0.001). Virologic breakthrough was observed for 12 patients, in the ETV group only. CONCLUSIONS: Add-on ADV was more effective and durable than ETV as rescue therapy. Therefore, add-on ADV might be the preferred strategy for LAM-resistant patients who need long-term antiviral treatment.

Full Text

Duke Authors

Cited Authors

  • Chung, GE; Kim, W; Lee, KL; Hwang, SY; Lee, J-H; Kim, HY; Jung, YJ; Kim, D; Jeong, JB; Kim, BG; Kim, YJ; Yoon, J-H; Lee, H-S

Published Date

  • July 2011

Published In

Volume / Issue

  • 56 / 7

Start / End Page

  • 2130 - 2136

PubMed ID

  • 21253834

Electronic International Standard Serial Number (EISSN)

  • 1573-2568

Digital Object Identifier (DOI)

  • 10.1007/s10620-010-1561-2

Language

  • eng

Conference Location

  • United States